- Home
- MRUS vs FOLD Comparison
MRUS vs FOLD Comparison
Compare MRUS & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- FOLD
- Stock Information
- Founded
- MRUS 2003
- FOLD 2002
- Country
- MRUS Netherlands
- FOLD United States
- Employees
- MRUS N/A
- FOLD N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- MRUS Health Care
- FOLD Health Care
- Exchange
- MRUS Nasdaq
- FOLD Nasdaq
- Market Cap
- MRUS 2.7B
- FOLD 2.9B
- IPO Year
- MRUS 2016
- FOLD 2007
- Fundamental
- Price
- MRUS $42.77
- FOLD $6.08
- Analyst Decision
- MRUS Strong Buy
- FOLD Buy
- Analyst Count
- MRUS 14
- FOLD 10
- Target Price
- MRUS $87.00
- FOLD $16.22
- AVG Volume (30 Days)
- MRUS 786.0K
- FOLD 4.6M
- Earning Date
- MRUS 05-07-2025
- FOLD 05-01-2025
- Dividend Yield
- MRUS N/A
- FOLD N/A
- EPS Growth
- MRUS N/A
- FOLD N/A
- EPS
- MRUS N/A
- FOLD N/A
- Revenue
- MRUS $54,732,000.00
- FOLD $543,141,000.00
- Revenue This Year
- MRUS $26.81
- FOLD $21.87
- Revenue Next Year
- MRUS $23.85
- FOLD $22.19
- P/E Ratio
- MRUS N/A
- FOLD N/A
- Revenue Growth
- MRUS N/A
- FOLD 28.25
- 52 Week Low
- MRUS $33.19
- FOLD $6.20
- 52 Week High
- MRUS $61.61
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- MRUS 49.60
- FOLD 29.58
- Support Level
- MRUS $37.92
- FOLD $6.63
- Resistance Level
- MRUS $46.36
- FOLD $7.71
- Average True Range (ATR)
- MRUS 2.56
- FOLD 0.30
- MACD
- MRUS -0.22
- FOLD -0.05
- Stochastic Oscillator
- MRUS 57.46
- FOLD 13.76
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.